Immunologic necessities: Diluents, adjuvants, and excipients

Hospital Pharmacy

Volumn 31, Issue 11, 1996, Pages 1387-1401

  Grabenstein, John D ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; POLYSORBATE 20;

CHEMICAL ANALYSIS; CHEMICAL REACTION KINETICS; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; MEDICAL LITERATURE; REVIEW; SERODIAGNOSIS;

EID: 0029840871     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Reilly WJ Jr. Pharmaceutical necessities. In: Gennaro AR, ed. Remington: The Science & Practice of Pharmacy. 19th ed. Easton, PA: Mack; 1995,1380-1416.
2. Reich I, Schnaare R, Sugita ET. Tonicity, osmoticity, osmolality, and osmolarity. In: Gennaro AR, ed. Remington: The Science & Practice of Pharmacy. 19th ed. Easton, PA: Mack; 1995,613-627.
3. Wade A, Weller PJ, ed. Handbook of Pharmaceutical Excipients. 2d ed. Washington, DC: American Pharmaceutical Association; 1994.
4. Niebergall PJ. Ionic solutions and electrolytic equilibria. In: Gennaro AR, ed. Remington:ne Science & Practice of Pharmacy. 19th ed. Easton, PA: Mack; 1995, 213-230.
5. Rouan SKE. Biotechnology-based pharmaceuticals. In: Banker GS, Rhodes CT, ed. Modem Pharmaceutics. 3d ed. New York: Marcel Dekker; 1996,843-873.
6. Parish HJ. A History of Immunizations. Edinburgh & London: E&S Livingstone Ltd; 1965.
7. Houck VN.Tuberculin: Past, present, and future.JAMA.1972;222:1421-1422.
8. Landi S, Held HR, Tseng MC. Evaluation of various substances to prevent adsorption of tuberculin purified protein derivative (PPD) to glass surfaces. Bull WHO. 1970; 43:91-106.
9. Grabenstein JD. ImmunoFacts: Vaccines & Immunologic Drugs. St. Louis: Facts & Comparisons, Inc.; November 1996.
10. Vadas EB. Stability of pharmaceutical products. In: Gennaro AR, ed. Remington: The Science & Practice of Pharmacy. 19th ed. Easton, PA: Mack; 1995:639-647.
11. Thompson GD, Thompson DF. The effect of the number of withdrawals on the sterility of multidose medication vials. J Clin Pharm Ther. 1992;17:61-64.
12. US Pharmacopeial Convention. United States Pharmacopeia: 23rd ed./National Formulary. Rockville, MD: USPC; 1995.
13. Centers for Disease Control. Hepatitis B associated with jet gun injection-California. MMWR. 1986;35:373-376.
14. Oren I, Hershow MD, Ben-Porath E, Krivoy N, Goldstein N, Rishpon S, Shouval D, Hadler SC, Alter MJ, Maynard JE, Alroy G. A common-source outbreak of fulminant hepatitis B in a hospital. Ann Intern Meet. 1989;110:691-698.
15. Centers for Disease Control. Improper infection-control practices during employee vaccination programs-District of Columbia and Pennsylvania, 1993. MMWR. 1993;42:969-971.
16. Boylan JC, Fites AL, Nail SL. Parenteral products. In: Banker GS, Rhodes CT, ed. Modern Pharmaceutics. 3d ed. New York: Marcel Dekker; 1996,441-487.
17. Bolger GR, Knapp DE, Reinstein PF, Gunter DA. FDA's drug quality reporting system. Consult Pharm. 1992;7:28-31.
18. Grabenstein JD. Allergen-extract compounding by pharmacists. Hosp Pharm. 1992;27:145,149-53,165.
19. Nelson HS. Effect of preservatives and conditions of storage on the potency of allergy extracts. J Allergy Clin Immunol. 1981;67:64-69.
20. Anderson MC, Baer H. Antigenic and allergenic changes during storage of a pollen extract. J Allergy Clin Immunol. 1982;69:3-10.
21. Niemeijer NR, Kauffman HF, van Hove W, Dubois AEJ, de Monchy JGR. Effect of dilution, temperature, and preservatives on the long-term stability of standardized inhalant allergen extracts. Ann Allergy Asthma Immunol. 1996;76:535-540.
22. NX'einer M, Bernstein IL. Adverse Reactions to Drug Formulation Agents: A Handbook of Excipients. New York: Marcel Dekker; 1989.
23. Van Metre TE Jr., Rosenberg GL.Vaswani SK, Ziegler SR.Adkinson NF. Pain and dermal reaction caused by injected glycerin in immunotherapy solutions. J Allergy Clin Immunol. 1996;97:1033-1039.
24. Grabenstein JD. Comment on sources of parenteral glycerol used in intracranial hypertension [letter]. Drug Intell Clin Pharm. 1985;19:56.
25. Grabenstein JD. Allergen patches: Testing for contact dermatitis. Hasp Pharm. 1996;31:419-420,423-425,429.
26. Edelman R. Vaccine adjuvants. Rev Infect Dis. 1980;2:370-383.
27. Warren HS.Vogel FR.Chedid LA. Current status of immunological adjuvants. Ann Rev Immunol. 1986;4:369-388.
28. Myers KR, Gustafson GL Adjuvants for human vaccine usage: A rational design. In: Cryz SJ Jr. Vaccines & Immunotherapy. New York: Pergamon Press; 1991,404-411.
29. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. Adjuvants: A balance between toxicity and adjuvanticity. Vaccine. 1993;11:293-306.
30. Grabenstein JD. Stop buying tetanus toxoid (with one exception). Hosp Pharm. 1990;25:361-362.
31. Petricciani JC, Horaud FN. DNA: Dragons and sanity. Biologicals. 1995;23:233-238.
32. McAleer WJ, Markus HZ, McLean AA, Buynak EB, Hilleman MR. Stability on storage at various temperatures of live measles, mumps and rubella virus vaccines in new stabilizer. / Biol Stand. 1980;8:281-287.
33. Hilleman MR. Improving the heat stability of vaccines: Problems, needs, and approaches. Rev Infect Dis. 1989;11(suppl. 3):S613-16.
34. Institute of Medicine. Temperature-Stable Vaccines for Developing Countries: Significance & Development Strategies. Washington, DC: National Academy Press; 1989.
35. Grabenstein JD, Kendal AP, Snyder RH. Storing, handling, and shipping immunologie drugs. Hasp Pharm. 1996;31:93&S,943-4,947-8.
36. Vogel FR, Powell ME A compendium of vaccine adjuvants and excipients. Pharmacent Biotechnol. 1995;6:141-228.
37. Tizard I. Veterinary Immunology: An Introduction. 4th ed. Philadelphia: WB Saunders Co.; 1992,261-276.
38. Davenport FM. Seventeen years' experience with mineral oil adjuvant influenza vaccines. Ann Allergy. 1968;26:288-292.